Search

everythinglearnresearchcommunity

for

Search:↓

Men with hair loss might have lichen planopilaris (LPP), which can mimic androgenetic alopecia, leading to misdiagnosis and ineffective treatment with finasteride or dutasteride. Proper diagnosis, including biopsies, is crucial to distinguish between androgenetic alopecia and conditions like LPP.

A user is considering using RU58841 for female pattern baldness and is also planning to use Minoxidil. They are hesitant to ask their doctor for spironolactone due to its cosmetic nature and are experiencing significant hair loss possibly due to stress and hormonal issues.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

The conversation discusses the potential benefits of sublingual minoxidil for hair loss treatment. It suggests that sublingual minoxidil, which bypasses the liver, may have fewer side effects, greater bioavailability, and could be more effective than oral minoxidil.

Quercetin and houttuynia cordata extract may stimulate hair growth by enhancing cellular energy metabolism and increasing growth factor secretion. Quercetin has low oral bioavailability, and its natural tint might stain the scalp if used topically.

A user has been on finasteride for 6 months and feels their hair quality has worsened, experiencing more hair loss and scalp irritation. They are considering seeing a dermatologist, while others suggest the issue might be unrelated to finasteride, possibly due to deficiencies or other conditions.

The user has been experiencing hair loss since having COVID and has low vitamin D levels; they are seeing some improvement in their crown and hairline after starting vitamin D supplements. Commenters suggest the hair loss pattern is consistent with male pattern baldness (MPD) and varies by individual.

How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.

Hair loss treatments and the user's progress with taking finasteride and minoxidil orally, which has resulted in full recovery after 5 months. Users commented on this progress and discussed their own experiences or confusion about the treatments used.

Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.

The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.

Carpronium chloride 5% is a hair growth treatment in Japan, considered less effective than minoxidil or finasteride. Some users report moderate success with it, but its efficacy is not well-verified.

The safety of using oral minoxidil to treat hair loss and thinning, with studies showing mild side effects at low doses. It was suggested that people should consult a doctor or dermatologist before taking any type of medication for hair loss.

User hoodoomoovoo discusses their interest in stem cell research and its potential for hair loss treatment. They share links to studies and mention ongoing trials, expressing optimism for a future solution to hair loss.

A 19-year-old male with diffuse and crown thinning is considering starting minoxidil as advised by a dermatologist but is unsure if he should seek a second opinion. Another user suggests consulting a reputable dermatologist to avoid wasting resources.

The user resumed taking 5mg oral minoxidil and 0.5mg dutasteride daily, with vitamins, and noticed hair regrowth. They switched from finasteride to dutasteride due to side effects and prefer oral minoxidil over topical for convenience and effectiveness.

A 23-year-old experienced reduced hair loss after three months of using oral minoxidil and dutasteride. The user reported no side effects and plans to continue the treatment.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

Stopping minoxidil can lead to significant hair loss, but resuming it along with finasteride can help regain lost hair over time. Consistency is key for maintaining hair health and regrowth.

Nanoxidil may be more effective than Minoxidil for hair loss due to better follicle penetration, but it lacks widespread recognition and research because it's owned by a small company and classified as a cosmetic. The pharmaceutical system favors Minoxidil due to its established market presence and profitability, leaving Nanoxidil largely unstudied and unknown.

A 28-year-old experienced hair loss and found success with daily 1mg Finasteride, noticing thicker hair without side effects. Despite this, their dermatologist suggested switching to expensive peptide serums, prompting the individual to seek a second opinion on long-term Finasteride and oral Minoxidil use.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Finasteride and Dutasteride do not cause depression or mood disorders; hair loss itself may be a more significant factor. Some users experience side effects from Finasteride, but it is generally well-tolerated.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

The user shared their positive experience with a hair transplant in South Korea, highlighting thorough consultations, consistent medical team involvement, and reasonable pricing. They noted good growth and natural-looking results after several months, with stem cell PRP treatment included to support graft survival.

South Korea's president is advocating for hereditary hair loss to be covered by national health insurance due to its impact on mental health and daily functioning. The discussion highlights the societal pressure in South Korea regarding appearance and the potential benefits of treating hair loss to improve mental health.

A 41-year-old South Asian individual feels hopeless about hair loss and cannot use oral finasteride or dutasteride due to existing gynecomastia. They are seeking advice on alternative treatments.

The user is experiencing scalp irritation from using RU58841 with a 70% ethanol and 30% propylene glycol vehicle and is considering switching to a less irritating vehicle, such as 30% ethanol with 70% squalane or emu oil. They are seeking feedback on the effectiveness and irritation levels of these alternative carriers.

PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.